articleThe LancetNov 1, 2011Closed access

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

LKLudwig KapposDLDavid LiPAPeter A. CalabresiPOPaul O’ConnorABAmit Bar‐Or

University Hospital of Basel · University of British Columbia · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

736
total citations
FWCI
33.07
Percentile
100%
References
30
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Ocrelizumab
  • Medicine
  • Placebo
  • Interferon beta-1a
  • Multiple sclerosis
  • Clinical endpoint
  • Internal medicine
  • Population
No related works found for this paper.

Funding